Europe Clears GSK’s New Twice-Yearly Asthma Treatment

The European Commission on Tuesday approved GSK plc’s (NYSE:GSK) Exdensur (depemokimab) in two indications, including: As an add-on maintenance treatment for severe asthma with type 2 inflammation, characterized by blood eosinophil count in adults and adolescents 12...